| FRAX486p21-activated kinase (PAK) inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.70%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
FRAX486 Dilution Calculator
calculate
FRAX486 Molarity Calculator
calculate
| Cas No. | 1232030-35-1 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | 6-(2,4-dichlorophenyl)-8-ethyl-2-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one | ||
| Canonical SMILES | O=C1C(C2=CC=C(Cl)C=C2Cl)=CC3=CN=C(NC4=CC=C(N5CCNCC5)C(F)=C4)N=C3N1CC | ||
| Formula | C25H23Cl2FN6O | M.Wt | 513.39 |
| Solubility | <2.59 mg/ml="" in="" dmso,=""><2.62 mg/ml="" in="" etoh,=""><2.56 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Physical Appearance | Yellow solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively
FRAX486 is a p21-activated kinase (PAK) inhibitor.
PAKs are known as effector proteins for the Rho GTPases Cdc42 and Rac. Both in vitro and in vivo studies have showed PAKs play critical roles for cytoskeletal organization and in various aspects of cell growth and development.
In vitro: Previous study showed in WPMY-1 cells, FRAX486 could dose-dependently induce the degeneration of actin filaments, which was accompanied by proliferation rate attenuation. Moreover, the FRAX486 cytotoxicity in WPMY-1 cells was found to be both time- and concentration-dependent. In addition, the effects of FRAX486 on actin organization, survival, and proliferation were observed at 1-5 μM in WPMY-1 cells, and complete inhibition of PAK1-3 might be expected, whereas PAK4 might be inhibited only partially at these concentrations [1].
In vivo: Animal study found that FRAX486 was able to cross the blood-brain barrier (BBB) and the brain therapeutical FRAX486 concentrations were detected as early as 1 h and remained as long as 24 h, with the maximum concentration (Cmax) at 8 h. Moreover, FRAX486 could reduce hyperactivity and stereotypical movements, both of which were phenotypes characterizing the Fragile X syndrome mouse model [2].
Clinical trial: Up to now, FRAX486 is still in the preclinical development stage.
References:[1] Wang Y,et al. P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate. PLoS One. 2016 Apr 12;11(4):e0153312. [2] Dolan BM,Duron SG,Campbell DA,Vollrath B,Shankaranarayana Rao BS,Ko HY,Lin GG,Govindarajan A,Choi SY,Tonegawa S. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5671-6.
